Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer

Clinical Breast Cancer

Volumn 5, Issue 2, 2004, Pages 142-147

  O'Shaughnessy, Joyce A ^a,b,c   Vukelja, Sasha ^b,c   Marsland, Thomas ^c   Kimmel, Gary ^b,c   Ratnam, Suresh ^b,c   Pippen, John E ^a,b,c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b TEXAS ONCOLOGY   (United States)

^c Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Combination therapy; Deoxycytidine analogue; HER2; Neutropenia; Targeted therapy

Indexed keywords

ANTHRACYCLINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; PACLITAXEL; PARACETAMOL; TAXANE DERIVATIVE; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASTHENIA; BACKACHE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SCORING SYSTEM; SOFT TISSUE METASTASIS;

EID: 3543091572     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.n.019     Document Type: Article

References (28)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
3. Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11:1936-1942.
4. Press MF, Pike MC, Chazin VR, et al. HER-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53:4960-4970.
5. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene 1995; 159:19-27.
6. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26:60-70.
7. Izumi Y, Xu L, di Tomaso E, et al. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416:279-280.
8. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a Single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726.
9. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and Safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648.
10. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a Monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N Eng J Med 2001; 344:783-792.
11. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and Vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19:2722-2730.
12. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16:2659-2671.
13. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:1800-1808.
14. Huang P, Chubb S, Hertel LW, et al. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51:6110-6117.
15. Gandhi V, Huang P, Xu YZ, et al. Metabolism and action of 2',2-difluorodeoxycitidine: self-potentiation of cytotoxicity. In: Harkness RA, Elion GB, Zollner N, eds. Purine and Pyrimidine Metabolism in Man, wol. 11, New York: Plenum Press, 1991:125-130.
16. Blackstein M, Vogel CL, Ambinder R, et al. Gemcitabine as first-line therapy in Patients with metastatic breast cancer: a phase II trial. Oncology 2002; 62:2-8.
17. Possinger K, Kaufmann M, Coleman R, et al. Phase II study of gemcitabine as First-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 1999; 10:155-162.
18. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13:2731-2736.
19. Spielmann M, Llombart-Cussac A, Kalla S, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001; 60:303-307.
20. Brodowicz T, Kostler WJ, Moslinger R, et al. Single-agent gemcitabine as second-and third-line treatment in metastatic breast cancer. Breast 2000; 9:338-342.
21. Carmichael J, Walling J. Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol 1996; 23:77-81.
22. Valerio MR, Cicero G, Armata MG, et al. Gemcitabine (G) in pretreated breast cancer (BC). Proc Am Soc Clin Oncol 2001; 20:51b (Abstract #1953).
23. Smorenburg CH, Bontenbal M, Seynaeve C, et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both on an anthracycline and a taxane. Breast Cancer Res Treat 2001; 66:83-87.
24. Bunn PA Jr, Helfrich B, Soriano AF, et al. Expression of HER-2/neu in human being cancer cell lines by immunohistochemistry and fluoroescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 2001; 7:3239-3250.
25. Nagourney RA, Evans SS, Chow C, et al. Trastuzumab (Herceptin) enhancement of cytotoxic drug activity in human tumor primary cultures. Breast Cancer Res Treat 1999; 57:116.
26. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18:2241-2251.
27. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9:1829-1838.
28. Sledge G. Gemcitabine combined with paclitaxel or paclitaxel/ trastuzumab in metastatic breast cancer. Semin Oncol 2003; 30 (2 suppl 3):19-21.